Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 August 2020 | Story Andre Damons | Photo Barend Nagel
Prof Motlalepula Matsabisa, Associate Professor in the Department of Pharmacology at the University of the Free State (UFS), has been appointed as the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Prof Motlalepula Matsabisa, Associate Professor in the Department of Pharmacology at the University of the Free State (UFS), will lead Africa’s fight against the COVID-19 pandemic with his appointment as chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Prof Matsabisa has been chosen over 25 other experts from 27 African countries to head this expert committee tasked with setting up research and clinical trials for COVID-19 and beyond. The committee is also supported by the African Union (AU), the Centers for Disease Control and Prevention (CDC – Africa), and the European and Developing Countries Clinical Trials Partnership (EDCTP).

This committee was established by the WHO and the Africa CDC on 22 July with the aim of providing independent scientific advice and support to countries on the safety, efficacy, and quality of traditional medicine therapies. It is also an effort to enhance research and development of traditional medicines for COVID-19 in Africa.

Looking forward

“This is a huge continental and global responsibility being laid on my shoulders as a chairperson.  I have to keep the committee together and ensure that it delivers on its set mandate and terms of reference.  I need to ensure that the committee helps the continent and region to get the scientific and legislative aspects on traditional medicine development on track.”  

“I have taken this position and responsibility, knowing quite well what it entails. I want to do this for the continent and for the sake of good science of all traditional healers and consumers of traditional medicines on the continent and beyond,” says Prof Matsabisa.

According to Prof Matsabisa, he is looking forward to working with a team of dedicated experts from 27 countries in the African region, and being of help to countries that need assistance with clinical trials, including preclinical work to move to clinical research.

Prof Matsabisa says he is also looking forward to countries asking South Africa to be part of their multi-centre studies in clinical trials for traditional medicines, and to help set up clinical trial teams that include Western-trained clinicians to get into traditional medicine studies. 

The work of the committee

According to Prof Matsabisa, his new position took effect the same day as his appointment and will run as long as COVID-19 is part of our daily lives and even beyond. It entails supporting member states to implement the WHO master plan for clinical trial protocols in order to generate credible data for COVID-19 results, based on traditional medicines. The committee will also coordinate support to member states in the African region to collaborate on clinical trials of traditional medicine-based therapies – elevating standards by pooling expertise in multicentre studies, as well as complying with GCP and good participatory practice guidelines for trials of emerging and re-emerging pathogens.
“The committee will also advise on strengthening the capacity of national medicine regulatory authorities to accelerate the issuance of marketing authorisations for traditional medicine products that have been well researched for safety, efficacy, and quality, as well as to expedite the approval of clinical trials on traditional medicines. This will help to meet the national registration criteria and the WHO norms and standards of quality, safety, and efficacy for the management of COVID-19 and others.”

“It will also provide independent scientific advice to the WHO and other partners regarding policies, strategies, and plans for integrating traditional medicines into COVID-19 responses and health systems,” explains Prof Matsabisa. 

Aiming for the top spot 

Prof Matsabisa has been described as having the third highest research output – something he is not satisfied with. 
“I was disappointed that only one point separated me from the second place. I will push for first place as this is my ultimate aim. My motivation for this is simple – I like what I am doing, I do not take it as a job but do it because I love research.”  

“I always like to tell students that we should be proud to one day see products in the shops that we can relate to and to which we have contributed or that we have made.   This is what drives me and my staff.  I have a beautiful team of students, staff, and postdoctoral fellows who share my vision of research.  We all have a shared vision and strive to be relevant at all times in science research, development, and teaching.”

• Prof Matsabisa was recently part of a national conference with the theme: Harnessing science, technology, and innovation in response to COVID-19: A national and international effort. The conference was hosted by Dr Blade Nzimande, Minister of Higher Education, Science and Innovation, with Pres Cyril Ramaphosa, Dr Zweli Mkhize, Minister of Health, Ebrahim Patel, Minister of Trade, Industry and Competition, Prof Sarah Anyang Agbor, African Union Commissioner for Human Resources, Science and Technology, and Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organisation, in attendance. 

News Archive

Small things matter
2017-01-17

 Description: Prof Felicity Burt  Tags: Prof Felicity Burt

Prof Felicity Burt (right) and Dr Dominique Goedhals
from the Department of Medical Microbiology and
Virology at the University of the Free State.
Photo: Anja Aucamp



The newly established virology section at the University of the Free State (UFS) boasts world class expertise. Not only are they one of just five laboratories in the country tasked with specialised HIV testing, but current research generates publications and subsidised funding.

The driving force behind this initiative is passionate and dedicated people who invest long hours into vital research. One such person is Prof Felicity Burt, who eloquently guides her students while making impressive progress within her own field of interest: vector-borne and zoonotic diseases. Prof Burt was recently awarded a research chair (2016-2020) to, among other areas, investigate medically significant vector-borne and zoonotic viruses currently circulating.

That means that her research focus is mainly on viruses transmitted by mosquitoes and ticks, and viruses transmitted from animals to humans. “Yes,” she laughs, “I catch mosquitoes and check them for viruses.”

Becoming familiar with different viruses
As if big screen moments like Outbreak and Contagion did not create enough virus paranoia, the world was recently bombarded by real world Ebola and Zika outbreaks. But awareness, Prof Burt says, is not a bad thing. “Years ago, when people heard that I did Ebola research, they got that distant look in their eyes, and changed the subject. One outbreak later, backed by many media reports, and Ebola is almost a household name. The same goes for the recent Zika virus outbreak in South America.”

The more familiar people become with these types of viruses, the better, Prof Burt feels. However, getting the right message across is not always that easy. The Zika virus outbreak, for example, was a very large outbreak and therefore presented large numbers of affected people. Generally, not everyone infected with an arbovirus will necessarily present with symptoms. But because vector-borne viruses can spread to new areas, surveillance and awareness is important. Here in Bloemfontein, Prof Burt and her team are establishing surveillance programmes.

Gaining knowledge and preventative measures
So, next time you get all wound up about a “biological disaster”, rest assured that competent people like Prof Burt and her colleagues continuously scan the environment to gain knowledge and develop preventive measures should any risks be looming. For example, developing next-generation vaccines that are very effective, but without risk – since they are not built on the virus itself, but only on the part of the virus that will induce an immune response.

Currently, Prof Burt is also looking into the relationship between the Sindbis virus and arthritis. It is clear that we can expect many exciting findings from the UFS’s new virology unit.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept